Harnessing the host immune response to infection – BCG immunotherapy for bladder cancer

Infection and Cancer: Bi-Directorial Interactions

Volumn , Issue , 2015, Pages 387-404

  Zdimerova, Hana ^a   Albert, Matthew L ^a   Ingersoll, Molly A ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Immunotherapy; Neutrophils

Indexed keywords

EID: 84957643330     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-20669-1_18     Document Type: Chapter

References (108)

1. Andersen P, Doherty TM (2005) The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3:656-662
2. Arnaud C, Braunersreuther V, Mach F (2005) Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15:202-206
3. BCG and cancer (1975). Can Med Assoc J 113(8):708-710
4. Biot C et al (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med
5. Bisiaux A et al (2009) Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. J Urol 181:1571-1580
6. Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD (1975) The effects of BCG on the dog bladder. Investig Urol 12:423-427
7. Boccafoschi C, Montefiore F, Pavesi M, Pastormerlo M, Betta PG (1995) Late effects of intravesical bacillus Calmette-Guerin immunotherapy on bladder mucosa infiltrating lymphocytes: an immunohistochemical study. Eur Urol 27:334-338
8. Bohle A et al (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 144:59-64
9. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoecon 21:1315-1330
10. Brandau S, Suttmann H (2007) Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61:299-305
11. Breban R et al (2012) Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. Oncoimmunol 1:9-17
12. Brinkmann V et al (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532-1535
13. Brosch R et al (2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 104:5596-5601
14. Chien YH, Zeng X, Prinz I (2013) The natural and the inducible: interleukin (IL)-17-producing gammadelta T cells. Trends Immunol 34:151-154
15. Cookson MS et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62-67
16. Cools-Lartigue J et al (2013) Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013 Aug 1; 123(8): 3446-3458
17. Coxon A, Tang T, Mayadas TN (1999) Cytokine-activated endothelial cells delay neutrophil apoptosis in vitro and in vivo. A role for granulocyte/macrophage colony-stimulating factor. J Exp Med 190:923-934
18. Czarnetzki BM et al (1993) Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 29A:1237-1242
19. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE (2008) Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 83:64-70
20. Davignon L, Robillard P, Lemonde P, Frappier A (1970) B.C.G. vaccination and leukemia mortality. Lancet 2:638
21. De Boer EC et al (1991) Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol Immunother 33:411-416
22. de Boer EC et al (1997) Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 25:31-34
23. de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH (2005) BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur Urol 48:333-338
24. De Larco JE, Wuertz BR, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10:4895-4900
25. Dyrskjot L et al (2012) Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer 107:116-122
26. Farid SG et al (2010) Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg 251:91-100
27. Ferlay J et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
28. Ferlay J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374-1403
29. Galdiero MR et al (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218:1402-1410
30. Gan C, Mostafid H, Khan MS, Lewis DJ (2013) BCG immunotherapy for bladder cancer-the effects of substrain differences. Nat Rev Urol 10:580-588
31. Gandhi NM, Morales A, Lamm DL (2013) Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int 112:288-297
32. Gutkin DW, Shurin MR (2014) Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother 63:45-57
33. Herr HW, Pinsky CM, Whitmore WF Jr, Oettgen HF, Melamed MR (1983) Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 51:1323-1326
34. Hoffmann P, Roumeguere T, Schulman C, van Velthoven R (2006) Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355:2705-2707
35. Hoption Cann SA, van Netten JP, van Netten C (2003) Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79:672-680
36. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP (2010) Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 70:6071-6082
37. Ingersoll MA, Albert ML (2013) From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 6:1041-1053
38. Jackson AM et al (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369-375
39. Kaplan AL, Litwin MS, Chamie K (2014) The future of bladder cancer care in the USA. Nat Rev Urol 11:59-62
40. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62-67
41. Kelley DR et al (1985) Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol 134:48-53
42. Kemp TJ et al (2005) Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 106:3474-3482
43. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21:467-476
44. Kreider JW, Bartlett GL, Boyer CM, Purnell DM (1979) Conditions for effective Bacillus Calmette-Guerin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma. Cancer Res 39:987-992
45. Lamm DL, Harris SC, Gittes RF (1977) Bacillus Calmette-Guerin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. Investig Urol 14:369-372
46. Lamm DL et al (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124:38-40
47. Lamm DL, Thor DE, Winters WD, Stogdill VD, Radwin HM (1981) BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer 48:82-88
48. Lattime EC, Gomella LG, McCue PA (1992) Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 52:4286-4290
49. Lerner SP (2005) Bladder cancer clinical trials. Urol Oncol 23:275-279
50. Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L (2012) Predictive biomarkers of bacillus Calmette-Guerin immunotherapy response in bladder cancer: where are we now? Adv Urol 2012:232-609
51. Lotan Y et al (2009) Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115:4096-4103
52. Luca S, Mihaescu T (2013) History of BCG vaccine. Maedica 8:53-58
53. Ludwig AT et al (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64:3386-3390
54. Luftenegger W et al (1996) Intravesical versus intravesical plus intradermal bacillus Calmette- Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 155:483-487
55. Mangtani P et al (2014) Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58:470-480
56. Marits P et al (2006) Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 49:59-70
57. Mathe G et al (1972) Attempts at stimulation of immune response in acute lymphoid leukaemia. Proc R Soc Med 65:266-270
58. Mavligit GM et al (1975) Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes’ C classification. Preliminary clinical results. Cancer 36:2421-2427
59. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P (2012) Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12:324-333
60. McKhann CF, Gunnarsson A (1974) Approaches to immunotherapy. Cancer 34(suppl): 1521-1531
61. Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180-183
62. Noon AP, Kulkarni GS (2014) All bacillus Calmette-Guerin (BCG) strains are equal, but some BCG strains are more equal than others. Eur Urol 66(4):689-691. doi:10.1016/j. eururo.2014.04.008, Epub 2014 Apr 28
63. Pan G et al (1997a) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818
64. Pan G et al (1997b) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113
65. Papayannopoulos V, Zychlinsky A (2009) NETs: a new strategy for using old weapons. Trends Immunol 30:513-521
66. Pinsky CM et al (1985) Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 69:47-53
67. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636-1642
68. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987a) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47:1762-1766
69. Ratliff TL, Gillen D, Catalona WJ (1987b) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155-158
70. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018-1023
71. Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol 11:153-162
72. Rentsch CA et al (2014) Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66(4):677-688. doi:10.1016/j. eururo.2014.02.061, Epub 2014 Mar 12
73. Riemensberger J, Bohle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127:20-26
74. Ritz N, Curtis N (2009) Mapping the global use of different BCG vaccine strains. Tuberculosis 89:248-251
75. Rosenberg SA (1975) Future prospects for immunotherapy. Cancer 36:821-824
76. Rosenthal SR et al (1972) BCG vaccination and leukemia mortality. JAMA 222:1543-1544
77. Saint F et al (2001) T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166:2142-2147
78. Saint F et al (2002) Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167:364-367
79. Sarica K et al (1995) Evaluation of cellular immunity following bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. Urol Int 54:137-141
80. Sarosdy MF, Lamm DL (1989) Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 142:719-722
81. Schmitz-Drager BJ et al (2014 Oct) Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol 32(7):1061-1068. doi:10.1016/j.urolonc.2013.10.010, Epub 2014 Jan 9
82. Schussler O et al (2006) Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 173:1161-1169
83. Schwentner C, Stenzl A, Gakis G (2012) Monitoring high-risk bladder cancer. Curr Opin Urol 22:421-426
84. Secanella-Fandos S, Luquin M, Julian E (2013) Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains. J Urol 189:711-718
85. Sengiku A et al (2013) A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 190:50-54
86. Sharma P et al (2003) Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 3:19
87. Sheridan JP et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821
88. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
89. Sievert KD et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27:295-300
90. Singer S et al (2013) Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer 21:1383-1393
91. Suttmann H, Lehan N, Bohle A, Brandau S (2003) Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guerin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect Immun 71:4647-4656
92. Suttmann H et al (2006) Neutrophil granulocytes are required for effective Bacillus Calmette- Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66:8250-8257
93. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964-1970
94. Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466-465; discussion 475-467
95. Takeuchi A et al (2011) IL-17 production by gammadelta T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer. Eur J Immunol 41:246-251
96. Tan JK, Ho VC (1993) Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 19:985-990
97. Tecchio C et al (2004) IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103:3837-3844
98. Thalmann GN, Dewald B, Baggiolini M, Studer UE (1997) Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158:1340-1344
99. Thalmann GN et al (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164:2129-2133
100. Torrado E, Robinson RT, Cooper AM (2011) Cellular response to mycobacteria: balancing protection and pathology. Trends Immunol 32:66-72
101. Watanabe E et al (2003) Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52:481-486
102. Wiley SR et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
103. Winters WD, Lamm DL (1981) Antibody responses to Bacillus Calmette-Guerin during immunotherapy in bladder cancer patients. Cancer Res 41:2672-2676
104. Wolfe SA, Tracey DE, Henney CS (1976) Introduction of “natural” killer’ cells by BCG. Nature 262:584-586
105. Zbar B, Rapp HJ (1974) Immunotherapy of guinea pig cancer with BCG. Cancer 34(suppl):1532-1540
106. Zbar B, Tanaka T (1971) Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172:271-273
107. Zhao W et al (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG- induced antitumor activity. Int J Cancer 86:83-88
108. Zuiverloon TC et al (2012) Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128-145